Ibuprofen and lipoic acid diamide as co-drug with neuroprotective activity: Pharmacological properties and effects in β-amyloid (1-40) infused Alzheimer's disease rat model

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 589-599

  Di Stefano, Antonio ^a   Sozio, P ^a   Cerasa, L S ^a   Iannitelli, A ^a   Cataldi, A ^a   Zara, S ^a   Giorgioni, G ^b   Nasuti, C ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Alzheimer's disease; Co drug; Lipoic acid; Neuroprotective agents; NSAIDs

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; IBUPROFEN; IBUPROFEN ALPHA THIOCTIC ACID; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PENETRATION; DRUG SCREENING; DRUG STRUCTURE; HISTOCHEMISTRY; LEARNING DISORDER; MALE; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RAT;

EID: 77955392823     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300221     Document Type: Article

References (33)

1. Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci 2006; 7:78.
2. Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev 2008; 60:1463-70.
3. Richardson RL, Kim EM, Shepard RA, Gardiner T, Geary J, O'Hare E. Behavioural and histopathological analyses of Ibuprofen treatment on the effect of aggregated Aβ(1-42) injections in the rat. Brain Res 2002; 954:1-10.
4. Cuadros MA, Navascues J. The origin and differentiation of microglial cells during development. Prog Neurobiol 1998; 56:173-89.
5. Kreutzberg GW. Microglial: a sensor for pathological events in CNS. Trends Neurosci 1996; 19:312-18.
6. Retz W, Gsell W, Münch G, Rosier M, Riederer P. Free radicals in Alzheimer's disease. J Neural Transm 1998; 54:221-36.
7. Stefanis L, Park DS, Friedman LA. Greene, caspase-dependent and independent death of camptothecin-treated embryonic cortical neurons. J Neurosci 1999; 19:6235-47.
8. Cardinaux JR, Allaman I, Magistretti PJ. Pro-inflammatory cytokines induce the transcription factors C/EBP-beta and C/EBP-delta in astrocytes. Glia 2000; 29:91-97.
9. Davis KL. NSAID and Alzheimer's disease; possible answers and new questions. Mol Psychiatr 2002, 7:925-926.
10. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414:212-6.
11. Smith WL, DeWitt D, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69:145-82.
12. Leuchtenberger S, Beher D, Weggen S. Selective modulation of Abeta-42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Curr Pharm Des 2006; 12:4337-55.
13. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 2005; 49:1088-99.
14. Hirohata M, Ono K, Yamada M. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des 2008; 14:3280-94.
15. Sharma M, Gupta YK. Effect of alpha lipoic acid on intracerebroventricular streptozotocin model of cognitive impairment in rats. Eur Neuropsychopharmacol 2003; 13:241-7.
16. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336:1216-22.
17. Martin A, Janigian D, Shukitt-Hale B, Prior RL, Joseph JA. Effect of vitamin E intake on levels of vitamins E and C in the central nervous system and peripheral tissues: implications for health recommendations. Brain Res 1999; 845:50-59.
18. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287:3230-7.
19. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61:82-8.
20. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997; 22:359-78.
21. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alphalipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radie Res 1999; 31:171-179.
22. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Münch G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007; 113:154-64.
23. Sozio P, D'Aurizio E, Iannitelli A, Cataldi A, Zara S, Cantalamessa F, Nasuti C, Di Stefano A. Ibuprofen and lipoic acid diamides as potential co-drugs with neuroprotective activity. Arch Pharm Chem Life Sci 2010, 343:133-142.
24. Wang R, Zhang HY, Tang XC. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol 2001; 421:149-56.
25. Nag E, Yee BK, Tang F. Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40). Brain Res Bull 1999; 50:251-62.
26. Begum AN, Yang F, Teng E, Hu S, Jones MR, Rosario ER, Beech W, Hudspeth B, Ubeda OJ, Cole GM, Frautschy SA. Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model. J Alzheimers Dis 2008; 15:625-40.
27. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, Ed 2. Academic, North Ryde, Australia. 1986.
28. Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM. Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain. J Neurosci 1998; 18:8311-21.
29. Stepanichev M, Zdobnova I, Zarubenko I, Lazareva N, Gulyaeva NV. Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25-35) on memory function and hippocampal damage in rat. Behav Brain Res 2006; 175:352-61.
30. Olton DS, Samuelson R. Remembrance of places passed spatial memory in rats. J Exp Psych 1976; 2:97-116.
31. Lamprecht A, Saumet JL, Roux J, Benoit JP. Lipid nanocarriers as drug delivery system for Ibuprofen in pain treatment. Int J Pharm 2004; 278:407-14.
32. Chen Q, Gong T, Liu J, Wang X, Fu H, Zhang Z. Synthesis, in vitro and in vivo characterization of glycosyl derivatives of Ibuprofen as novel prodrugs for brain drug delivery. J Drug Target 2009; 17:318-28.
33. Contò MB, de Carvalho JG, Benedito MA. Behavioral differences between subgroups of rats with high and low threshold to clonic convulsions induced by DMCM, a benzodiazepine inverse agonist. Pharmacol Biochem Behav 2005; 82:417-26.